
MBBS MD DM. Consultant nephrologist, AIMS Thrissur. @glomcon fellow 2022-23. @KidneyKolumns EB member 2024-25. @winicon2024 #SoMe team.
Kerala, India
Joined April 2022
- Tweets886
- Following396
- Followers319
- Likes277
Dr. Ambily K retweeted
An excellent #Onconephrology session with Dr @kdjhaveri on glomerular diseases in malignancy, followed by insightful case discussions by Dr @GuhanS1804 & Dr @drambilyk , with valuable perspectives from Dr @raja_1980. Great learning! 👏 #Glomerulonephritis #ISN_SAARC_OncoNeph
Dr. Ambily K retweeted
🎇Opening session of the ISN-SAARC Onconephrology Course 2026 begins with an insightful lecture by Dr. @kdjhaveri, moderated by Dr @vjha126.
🎉Excited to share our journey with our new bunch of candidates.
#Onconephrology #NephTwitter
Dr. Ambily K retweeted
💥Kickstarting the ISN-SAARC Onconeph Course 2026
🎓 Introductory session on onconephrology by Dr
@kdjhaveri
📍 Exploring the intersection of kidney disease and cancer care.
#Onconephrology #Nephrology #MedicalEducation #KidneyHealth #CancerCare
Dr. Ambily K retweeted
Thrilled to announce the selected candidates for the ISN SAARC Onconephrology Fellowship 2026! Welcome to the cohort - ready to advance kidney care in cancer patients across the region. Congratulations to all! #ISNSAARC2026 #Onconephrology #Nephrology
Dr. Ambily K retweeted
Obesity in CKD: Core Curriculum 2026
ajkd.org/article/S0272-6386%…
Dr. Ambily K retweeted
🧠 Post Renal Transplant Infections Timeline – Must Know!
🕒 0–1 month (Surgical phase)
• Nosocomial infections dominate
• UTI, SSI, pneumonia
• Not immunosuppression-driven
🕒 1–6 months (🔥 Peak immunosuppression)
• Opportunistic infections
• Cytomegalovirus infection (most common)
• Pneumocystis jirovecii pneumonia, TB, fungi
• BK virus nephropathy
🕒 >6 months (Community phase)
• CAP, UTI, influenza
• Late CMV, PCP (if no prophylaxis)
• Post-transplant lymphoproliferative disorder
💡 Pearls:
✔ Timeline = diagnosis shortcut
✔ CMV = key player
✔ Think TB in India
✔ TMP-SMX prophylaxis saves lives
#GSR #BuddingNephros #Transplant #Infection
Dr. Ambily K retweeted
Sunday morning quiz
Which blood component has highest sensitizong event when given to kidney transplant recipients?🩸🩸
Is it
A. PACKED RED BLOOD CELLS
B. Whole blood
C. Leucodepleted PCV
D. Platelets
???
Platelets have upto 10* higher HLA expression 🩸🩸
Remember this next time you order SdP for ur patients
Dr. Ambily K retweeted
Optimal glucocorticoid therapy in lupus nephritis
doi.org/10.1093/ndt/gfae294
Dr. Ambily K retweeted
🫀 Diuretic Resistance in Cardiorenal Syndrome: Are We Treating the Wrong Target?
A recent review in Frontiers in Cardiovascular Medicine challenges a deeply ingrained paradigm in heart failure management:
👉 That congestion is simply a “fluid problem.”
In reality, diuretic resistance (DR) is not failure of therapy, it is failure of understanding physiology.
🔬 The Core Insight
Up to 1 in 3 HF patients will not respond adequately to loop diuretics.
But the mechanism is not just “insufficient dose.”
It is a multisystem adaptive response:
↓ Renal perfusion + ↑ venous congestion
Tubular remodeling (distal sodium avidity)
Neurohormonal activation (RAAS, SNS)
Chloride depletion → a neglected driver of resistance
👉 We are not dealing with “volume overload”
👉 We are dealing with a sodium-retentive, neurohormonally activated organ
⚠️ The Clinical Mistake
We still rely on:
Weight
Fluid balance
Creatinine
These are late, indirect, and often misleading markers.
Meanwhile, the kidney has already adapted.
📊 The Paradigm Shift
The paper reinforces a critical transition toward:
1. Physiology-guided monitoring
Urinary sodium (UNa) at 1-2h
Urine output kinetics
POCUS (VExUS, lung ultrasound)
2. Mechanism-based therapy
Sequential nephron blockade
Chloride repletion (not just sodium restriction)
Early combination strategies
3. Phenotype-specific management
Not all HF is the same:
Right heart failure → venous congestion-driven DR
CKD → pharmacokinetic + tubular limitations
Obesity → hidden congestion + inflammatory sodium retention
Frailty → narrow therapeutic window
👉 Same drug, different physiology, different response
🧠 The Take-Home Message
Diuretic resistance is not a pharmacologic problem.
It is a systems physiology problem.
And until we treat:
Renal perfusion
Venous congestion
Electrolyte signaling (chloride!)
Patient phenotype
👉 We will continue escalating doses…
👉 …instead of improving outcomes.
🚀 My Perspective
We are moving toward a future where:
UNa replaces weight as the primary feedback loop
POCUS becomes mandatory, not optional
If you're managing HF patients daily:
Are you still chasing urine… or understanding the kidney?
📃Reference
Aletras, G., etc al. Frontiers in Cardiovascular Medicine, 12, 1731305.
doi.org/10.3389/fcvm.2025.17…
Dr. Ambily K retweeted
💊 How Tacrolimus Reduces Proteinuria –
Tacrolimus works beyond immunosuppression 👇
🔹 🧬 Podocyte stabilization (KEY) Preserves synaptopodin → maintains actin cytoskeleton → ↓ foot process effacement → rapid ↓ proteinuria
🔹 🛡️ Anti-apoptotic effect Inhibits calcineurin–NFAT pathway → ↓ podocyte apoptosis → preserves podocyte number → slows progression
🔹 Immunological action ↓ T-cell activation & cytokines → ↓ immune-mediated glomerular injury
🔹 ⚖️ Hemodynamic effect (secondary)
Afferent vasoconstriction → ↓ intraglomerular pressure → ↓ protein filtration
#GSR #BuddingNephros
#Nephrology #Tacrolimus #Proteinuria #Podocyte
Dr. Ambily K retweeted
💉DKA is not a glucose problem.
It’s a metabolic collapse.
We often simplify diabetic ketoacidosis as:
❌ “Severe hyperglycemia”
But that’s misleading.
👉 You can have normal glucose and still be in DKA
1. What really defines DKA
The classic triad:
Hyperglycemia
Anion gap metabolic acidosis
Ketonemia
But the key driver is:
👉 Insulin deficiency → unchecked ketogenesis
2. The dangerous trap: Euglycemic DKA
Up to ~3% of patients present with:
Glucose <250 mg/dL
Severe acidosis
High anion gap
-Common triggers:
SGLT2 inhibitors
Pregnancy
Starvation
👉 If you wait for hyperglycemia…
👉 You will miss it.
3. Think in triggers: the “5 I’s”
Infection
Infarction
Insulin (non-adherence)
Intoxication
Infant (pregnancy)
👉 DKA is always a consequence, not the disease itself.
4. The physiology most people forget
Total body potassium = LOW
Serum potassium = often NORMAL or HIGH
Why?
👉 Acidosis shifts K⁺ out of cells
Then you give insulin →
⚠️ Potassium crashes
5. The biggest treatment mistake
Stopping insulin too early.
👉 Insulin is NOT for glucose
👉 Insulin is for ketosis ⚠️
Never stop insulin until:
Anion gap closes
Bicarbonate normalizes
6. Fluids matter more than you think
Patients are often:
👉 4–6 liters depleted
And interestingly:
Balanced crystalloids may improve outcomes⚠️
Avoid hyperchloremic acidosis
7. The mindset shift
DKA management is not:
❌ “Lower glucose”
It is:
✅ Stop ketogenesis
✅ Restore volume
✅ Correct electrolytes
✅ Treat the trigger
🤓Final message
If you remember only one thing:
👉 Normal glucose does NOT exclude DKA
📃Reference
Lowie BJ. Endocrinol Metab Clin N Am 55 (2026) 1–10 doi.org/10.1016/j.ecl.2025.0…
Dr. Ambily K retweeted
The five primary clinical presentations of Diabetic Neuropathies.
It categorizes nerve damage based on the type of fibers affected and the anatomical distribution of symptoms.
link.springer.com/rwe/10.100…
Dr. Ambily K retweeted
HF + CKD = treat by EF + eGFR 🎯
✅HFrEF:
<15 → β-blocker + nitrates
15–29 → + SGLT2i (>20) ± vericiguat
30–59 → + ARNI/ACEi/ARB + MRA
≥60 → full GDMT
✅HFpEF:
SGLT2i backbone; add nsMRA (>25), ARNI if EF ~50%
@goKDIGO
pubmed.ncbi.nlm.nih.gov/4179…
Dr. Ambily K retweeted
#ResistantHypertension affects approximately 10% of patients treated for #hypertension and is associated with increased #cardiovascular mortality compared with controlled blood pressure.
📄 Learn more in this Review: ja.ma/4bExPSl

ALT Algorithm for the management of resistant hypertension from JAMA. Key steps: Patient presents with apparent resistant hypertension (HTN); Screening for white-coat effect (WCE); Assessment of medication adherence; Screening for secondary causes of HTN; Confirmation of true resistant HTN; Treatment.
Dr. Ambily K retweeted
KDIGO 2026 AKI/AKD guidelines
Key takeaway kdigo.org/guidelines/acute-k…
Dr. Ambily K retweeted
KDIGO 2026 Diabetes and CKD guidelines .
Key Points.
kdigo.org/wp-content/uploads…
Dr. Ambily K retweeted
Membranous Nephropathy
🔬Anti-PLA2R= diagnosis,prognosis,monitoring
📊Risk stratify:Proteinuria+eGFR+PLA2R
🟢 Low risk→ Supportive
🟡 Mod→ Observe ± RTX
🔴 High→ Rituximab / Cyclophosphamide+Steroids
👍for Antigens: VA @KKNephBytes 💯
#Nephrology #KDIGO
Dr. Ambily K retweeted
🚨 Resistant Hypertension: From “Apparent” to “True” — Precision Matters (JAMA 2026)
🔬 Definition & Epidemiology — Not All Resistant HTN is Real
Apparent resistant HTN = BP ≥130/80 mm Hg despite ≥3 drugs (ACEi/ARB + CCB + thiazide) at optimal doses
~20% of treated hypertensives fall into this category
BUT → True resistant HTN ≈10% only after exclusion of:
White-coat effect (~37.5%)
Nonadherence (~50%)
Secondary causes (~5–25%)
👉 Clinical message: Most “resistant HTN” is pseudo-resistant → diagnosis refinement is critical
🧠 Stepwise Diagnostic Algorithm (High-Yield Clinical Thinking)
1️⃣ Exclude White-Coat Effect
Home BP <130/80 OR ABPM <125/75 mm Hg
➡️ Continue monitoring, no overtreatment
2️⃣ Assess Adherence (Underrated Step)
Use refill data / drug assays
Address:
Cost barriers
Adverse effects
Cognitive issues
3️⃣ Screen Secondary Causes
Primary aldosteronism (commonest)
CKD, OSA, obesity, drugs (NSAIDs, SNRIs, cocaine)
👉 Only after this → TRUE resistant HTN confirmed
⚠️ Why It Matters (Prognostic Impact)
↑ Cardiovascular mortality risk (absolute ↑ ~10% over 5–10 yrs)
Strong association with:
Diabetes
CKD
Obesity
Sleep apnea
🧬 Therapeutic Strategy — CME India Algorithmic Pearls
🔹 Step 1: Lifestyle (Foundation Therapy)
Sodium <1500 mg/day
Weight loss + exercise ≥150 min/week
Avoid alcohol, offending drugs
Treat OSA
👉 Often neglected but high-yield in India
🔹 Step 2: Optimize Triple Therapy
Prefer single-pill combinations (↑ adherence, ↓ SBP ~4 mmHg)
Diuretic optimization:
Chlorthalidone > thiazide (especially CKD)
Add loop diuretic if eGFR <30
🔹 Step 3: Add Mineralocorticoid Receptor Antagonist (MRA) — ⭐ GAME CHANGER
Spironolactone 25–50 mg/day
↓ Office SBP: ~13 mmHg
↓ Ambulatory SBP: ~8 mmHg
Criteria:
eGFR ≥45 ml/min
K⁺ ≤4.5 mmol/L
👉 Most effective add-on therapy in resistant HTN
🔹 If Spironolactone Intolerance
Amiloride (non-inferior)
Eplerenone (less potent, fewer endocrine effects)
🔹 Step 4: Sequential Add-ons
β-blockers
α1-blockers (doxazosin)
Central agents (clonidine)
Non-DHP CCB
Vasodilators
Aprocitentan (dual endothelin antagonist — emerging option)
🔹 Step 5: Device Therapy
Renal denervation
↓ Ambulatory SBP ~4.4 mmHg
↓ Office SBP ~6.6 mmHg
👉 For selected refractory cases
💊 Drug Hierarchy (Practical Take-Home)
👉 Best Add-On:
✔️ Spironolactone > all others
👉 Alternatives:
✔️ Amiloride ≈ spironolactone
✔️ Eplerenone (safer endocrine profile)
👉 Less Effective / Add-on:
β-blockers, α-blockers, clonidine
👉 New Kid:
Aprocitentan (modest effect, fluid retention risk)
⚠️ Adverse Effect Awareness
Spironolactone:
Hyperkalemia (3–5%)
Gynecomastia (~5–9%)
Clonidine:
Rebound HTN
α-blockers:
Orthostatic hypotension
🎯 CME INDIA CLINICAL PEARLS
🔴 “Resistant HTN is often diagnostic failure, not therapeutic failure”
🔴 “Half of resistant HTN = nonadherence → always check before escalating”
🔴 “Chlorthalidone + Spironolactone = backbone of resistant HTN therapy”
🔴 “Primary aldosteronism is underdiagnosed → think beyond essential HTN”
🔴 “Single-pill combinations are not convenience—they are outcome modifiers”
🔴 “Renal denervation: modest BP fall but useful in selected refractory cases”
📚 Key Reference (Journal Format)
Carey RM, et al. Resistant Hypertension: Diagnosis and Management. JAMA. 2026; doi:10.1001/jama.2026.2846682
jamanetwork.com/journals/jam…













































